Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years.

@article{Romanowski2009SustainedEA,
  title={Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years.},
  author={Barbara Romanowski and P Colares de Borba and P. Naud and Cecilia Maria Roteli-Martins and Newton S{\'e}rgio de Carvalho and J{\'u}lio C{\'e}sar Canfield Teixeira and Fred Aoki and Brian R Ramjattan and R Michael Shier and Rajan B Somani and Sylvaine Barbier and Mark M Blatter and Christina Chambers and Daron G. Ferris and Stanley A. Gall and Fernando A. D. R. A. Guerra and Diane Medved Harper and James A Hedrick and Dan C Henry and Abner P Korn and Robin Kroll and Anna-Barbara Moscicki and Walter D Rosenfeld and Bradley J Sullivan and Christopher Thoming and Stephen Keith Tyring and Cosette Marie Wheeler and Gary O. Dubin and Anne E Schuind and Toufik Zahaf and Mary Greenacre and An Sgriobhadair},
  journal={Lancet},
  year={2009},
  volume={374 9706},
  pages={1975-85}
}
BACKGROUND Prophylactic human papillomavirus (HPV) vaccines have to provide sustained protection. We assessed efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine up to 6.4 years. METHODS Women aged 15-25 years, with normal cervical cytology, who were HPV-16/18 seronegative and oncogenic HPV DNA-negative (14 types) at screening… CONTINUE READING